Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Subscribe To Our Newsletter & Stay Updated
